---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-24-001007"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:42:44.717145+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immunic Q2 net loss $21.4M ($0.21/shr); appoints COO/President Tardio, Board member Skerjanec

## Summary
- Net loss of $21.4M for Q2 2024 vs $24.0M Q2 2023; diluted EPS -$0.21 on 101.3M shares.
- Cash $79.7M as of June 30, 2024; expects runway into Q3 2025.
- Jason Tardio (ex-Novartis, Biogen) appointed COO and President effective July 12, 2024.
- Simona Skerjanec (ex-Roche Neuroscience head) joined Board of Directors July 22, 2024.
- Phase 2 CALLIPER top-line data for vidofludimus calcium in PMS expected April 2025; ENSURE Phase 3 RMS trials on track.

## SEC filing metadata
- accession: 0001193805-24-001007
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380524001007/0001193805-24-001007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380524001007/e663826_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-24-001007
- JSON: https://secwatch.observer/filing/0001193805-24-001007.json
- Plain text: https://secwatch.observer/filing/0001193805-24-001007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.